LENZ Therapeutics Reports Progress on VIZZ Adoption and Patient Persistence in Second Quarter
LENZ Therapeutics (NASDAQ: LENZ) provided an update during its Q2 2026 earnings call, highlighting progress with the adoption of its product VIZZ. The company noted a significant increase in new patient starts following the launch of telehealth and expanded marketing efforts on national TV in July. Month-over-month total prescriptions grew by over 45%. CEO Evert Schimmelpennink emphasized that while Q2 showed modest growth, early results are encouraging. The call also focused on patient persistence metrics. Over 60% of e-pharmacy patients who purchased VIZZ have bought more than one multipack, indicating repeat purchasing behavior. The company noted promising refill patterns among the first three cohorts since launch (Q4 25 to Q2 26), with an average annualized purchase rate approaching five monthly packs. LENZ highlighted that e-pharmacy remains its dominant sales channel and a key source of detailed patient data, which is helping shape priorities for the second half of the year.
Tickers: $LENZ